Bank OZK Reduces Position in Pfizer Inc. (NYSE:PFE)

Bank OZK trimmed its position in Pfizer Inc. (NYSE:PFE) by 11.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,706 shares of the biopharmaceutical company’s stock after selling 4,163 shares during the quarter. Bank OZK’s holdings in Pfizer were worth $913,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Investment Advisory Services Inc. TX ADV boosted its holdings in Pfizer by 1.6% in the 3rd quarter. Investment Advisory Services Inc. TX ADV now owns 20,097 shares of the biopharmaceutical company’s stock valued at $667,000 after purchasing an additional 325 shares during the last quarter. Trifecta Capital Advisors LLC boosted its holdings in Pfizer by 3.7% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 325 shares during the last quarter. Powers Advisory Group LLC boosted its holdings in Pfizer by 2.4% in the 3rd quarter. Powers Advisory Group LLC now owns 13,759 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 329 shares during the last quarter. Confluence Wealth Services Inc. boosted its holdings in Pfizer by 0.5% in the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after purchasing an additional 342 shares during the last quarter. Finally, Carr Financial Group Corp boosted its holdings in Pfizer by 3.3% in the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 355 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.6 %

NYSE:PFE traded up $0.14 during midday trading on Friday, reaching $25.40. The company had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. The firm has a market capitalization of $143.83 billion, a price-to-earnings ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61. The stock’s fifty day simple moving average is $26.96 and its 200-day simple moving average is $28.42. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.14 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.61%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.